Quest Diagnostics Short Interest Down 18.3% in April (DGX)
Quest Diagnostics (NYSE:DGX) saw a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 20,253,167 shares, a decline of 18.3% from the March 31st total of 24,797,304 shares, Analyst Ratings Network reports. Approximately 14.1% of the shares of the stock are short sold. Based on an average trading volume of 2,888,589 shares, the short-interest ratio is presently 7.0 days.
In other Quest Diagnostics news, CFO Mark Guinan bought 4,000 shares of the stock on the open market in a transaction that occurred on Monday, May 5th. The stock was purchased at an average price of $55.51 per share, with a total value of $222,040.00. Following the completion of the acquisition, the chief financial officer now directly owns 44,222 shares of the company’s stock, valued at approximately $2,454,763. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
DGX has been the subject of a number of recent research reports. Analysts at Zacks upgraded shares of Quest Diagnostics from an “underperform” rating to a “neutral” rating in a research note on Thursday. They now have a $58.00 price target on the stock, up previously from $50.00. Separately, analysts at Bank of America upgraded shares of Quest Diagnostics from an “underperform” rating to a “neutral” rating in a research note on Thursday. They now have a $58.00 price target on the stock. Finally, analysts at Credit Suisse raised their price target on shares of Quest Diagnostics from $55.00 to $62.00 in a research note on Monday, April 14th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $59.82.
Quest Diagnostics (NYSE:DGX) opened at 57.27 on Friday. Quest Diagnostics has a 52-week low of $50.46 and a 52-week high of $64.10. The stock’s 50-day moving average is $57.82 and its 200-day moving average is $56.46. The company has a market cap of $8.275 billion and a price-to-earnings ratio of 10.24.
Quest Diagnostics (NYSE:DGX) last released its earnings data on Thursday, April 24th. The company reported $0.84 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.89 by $0.05. The company had revenue of $1.75 billion for the quarter, compared to the consensus estimate of $1.75 billion. During the same quarter last year, the company posted $0.89 earnings per share. Quest Diagnostics’s revenue was down 2.3% compared to the same quarter last year. On average, analysts predict that Quest Diagnostics will post $4.02 earnings per share for the current fiscal year.
Quest Diagnostics Incorporated (NYSE:DGX), is a provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.